April 2014, Vol 5, No 3

Quality Research and Patient Safety Abstract from the 4th Annual AVBCC Conference.

Policy, Advocacy, and Economy Abstacts from the 4th Annual AVBCC Conference.

Patient and Survivor Care Abstracts from the 4th Annual AVBCC Conference.

Oncology Practice Management, Navigation, & Advocacy Day Abstracts from the 4th Annual AVBCC Conference.

Models of Care Delivery Abstracts from the 4th Annual AVBCC Conference.

Innovation in Practice Management Abstract from the 4th Annual AVBCC Conference.

Improving Patient Access, Initiation, and Adherence Abstract from the 4th Annual AVBCC Conference.

Benefit Design and Coverage Trends Abstract from the 4th Annual AVBCC Conference

Advocacy and Community Involvement Abstract from the 4th Annual AVBCC Conference

Hollywood, FL—The updated National Comprehensive Cancer Network (NCCN) guidelines for the management of melanoma now include the BRAF inhibitor dabrafenib (Tafinlar) as a Category 1 recommendation for the primary treatment of patients with metastatic melanoma and BRAF mutation, as well as the use of the mitogen-activated protein kinase (MEK) inhibitor trametinib (Mekinist) for the treatment of patients with melanoma and BRAF mutation. These 2 drugs, which received US Food and Drug Administration (FDA) approval last year, are now added to the NCCN targeted therapies for the treatment of patients with advanced or metastatic melanoma.